0000000001103054

AUTHOR

Christian Enzinger

showing 4 related works from this author

Acute Cerebrovascular Disease in the Young

2013

Background and Purpose— Strokes have especially devastating implications if they occur early in life; however, only limited information exists on the characteristics of acute cerebrovascular disease in young adults. Although risk factors and manifestation of atherosclerosis are commonly associated with stroke in the elderly, recent data suggests different causes for stroke in the young. We initiated the prospective, multinational European study Stroke in Young Fabry Patients (sifap) to characterize a cohort of young stroke patients. Methods— Overall, 5023 patients aged 18 to 55 years with the diagnosis of ischemic stroke (3396), hemorrhagic stroke (271), transient ischemic attack (1071) we…

AdultMalemedicine.medical_specialtyPediatricsAdolescentischemiccauseCohort StudiesYoung AdultRisk FactorsmedicineHumansrisk factorsProspective Studiescardiovascular diseasesYoung adultProspective cohort studyStrokeAdvanced and Specialized NursingIntracerebral hemorrhageFabry diseaseCerebral infarctionbusiness.industryAge Factorsimagingyoung strokeMiddle Agedmedicine.diseaseintracerebral hemorrhagestrokeFabry diseaseEuropeStrokeCerebrovascular DisordersNeurologytransient ischemic attackAcute DiseaseCohortPhysical therapyFabry DiseaseFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCohort studyStroke
researchProduct

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

2021

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particular…

Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine & healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers

2006

Background: Previous studies have examined the role of APOE variation in multiple sclerosis (MS), but have lacked the statistical power to detect modest genetic influences on risk and disease severity. The meta- and pooled analyses presented here utilize the largest collection, to date, of MS cases, controls, and families genotyped for the APOE epsilon polymorphism. Methods: Studies of MS and APOE were identified by searches of PubMed, Biosis, Web of Science, Cochrane Review, and Embase. When possible, authors were contacted for individual genotype data. Meta-analyses of MS case-control data and family-based analyses were performed to assess the association of APOE epsilon genotype with dis…

Apolipoprotein EOncologyRiskmedicine.medical_specialtyPathologyMultiple SclerosisGenotypeApolipoprotein E2Apolipoprotein E4Polymorphism Single NucleotideSeverity of Illness IndexLinkage DisequilibriumPrimary progressiveCentral nervous system disease03 medical and health sciences0302 clinical medicineApolipoproteins EDisease severityPolymorphism (computer science)Internal medicineGenotypemedicineHumansGenetic Predisposition to Disease10. No inequalityAlleles030304 developmental biology0303 health sciencesExpanded Disability Status ScalePolymorphism GeneticScience & Technologybusiness.industryMultiple sclerosismedicine.disease3. Good healthPedigreePhenotypeCase-Control StudiesSettore MED/26 - NeurologiaNeurology (clinical)businessMultiple Sclerosis APOE disease severity meta-analysis030217 neurology & neurosurgery
researchProduct

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

2022

[Background and Purpose] Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.

StrokeVaccine-induced immune thrombotic thrombocytopeniaSDG 3 - Good Health and Well-beingCerebral venous thrombosisSARS-CoV-23112 NeurosciencesCOVID-19COVID-19; Cerebral venous thrombosis; Vaccine-induced immune thrombotic thrombocytopenia; Mortality; SARS-CoV-2; StrokeNeurology (clinical)MortalityCardiology and Cardiovascular Medicine3124 Neurology and psychiatryCOVID-19; Cerebral venous thrombosis; Mortality; SARS-CoV-2; Stroke; Vaccine-induced immune thrombotic thrombocytopeniaJournal of Stroke
researchProduct